Anti-Ebola therapy (RedHill Biopharma)(Anti-Ebola therapy (RedHill Biopharma))

概要

基本信息

药物类型

未知

别名-

靶点-

作用机制

免疫调节剂

治疗领域

感染其他疾病

在研适应症-

非在研适应症

埃博拉病毒性疾病

原研机构

RedHill Biopharma Ltd.

在研机构-

非在研机构

RedHill Biopharma Ltd.

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Anti-Ebola therapy (RedHill Biopharma) 相关的临床结果

登录后查看更多信息

100 项与 Anti-Ebola therapy (RedHill Biopharma) 相关的转化医学

登录后查看更多信息

100 项与 Anti-Ebola therapy (RedHill Biopharma) 相关的专利（医药）

登录后查看更多信息

1

项与 Anti-Ebola therapy (RedHill Biopharma) 相关的文献（医药）

1998-02-13·Science1区 · 综合性期刊

A Method in Ebola's Madness

1区 · 综合性期刊

Communications

作者: Wickelgren, Ingrid

INFECTIOUS DISEASESOn page [1034][1], a team of molecular virologists reports results suggesting that the Ebola virus uses different versions of the same glycoprotein--a protein with sugar groups attached--to wage a two-pronged attack on the body. One glycoprotein, secreted by the virus, seems to paralyze the inflammatory response that should fight it off, while the other, which stays bound to Ebola, homes in on the endothelial cells lining the blood vessels, helping the virus infect and damage them. If confirmed in infected animals and humans, the findings suggest that these glycoproteins could be targets for anti-Ebola vaccines as well as for drugs that treat Ebola infections. [1]: http://www.sciencemag.org/cgi/content/short/279/5353/1034

100 项与 Anti-Ebola therapy (RedHill Biopharma) 相关的药物交易

登录后查看更多信息